Liver Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• Adults between 18 and 75 years of age (inclusive).
• People who have not previously received systemic cancer treatment, or who meet the criteria for spleen removal during treatment.
• People diagnosed with liver cancer (hepatocellular carcinoma) that cannot be surgically removed, or that has come back after surgery.
• People with hepatitis B virus (HBV) levels below a certain threshold who are already receiving antiviral treatment.
• People who are generally able to carry out daily activities with little to no limitation, and whose major organs are functioning adequately.
• People with a liver health score (Child-Pugh score) of 5 to 7, indicating mild to moderate liver disease.
• People whose spleen measures more than 4.0 cm in thickness.
• People with a history of enlarged veins in the food pipe or stomach (varices), warning signs on those veins (red signs), or bleeding from those veins, with or without an enlarged spleen.
• People with an enlarged spleen and low white blood cell and platelet counts meeting specific thresholds (confirm with trial site for exact numbers).
• People whose liver enzyme levels, bilirubin, clotting measures, and kidney function all fall within specific acceptable ranges (confirm with trial site for exact values).
• People who are suitable to receive certain local liver treatments, such as TACE, HAIC, radiation with yttrium-90, targeted radiation therapy (SBRT), or tumour ablation techniques.
• People who are willing and able to give informed consent to participate.
• People with an expected survival of more than 3 months.

Who may not be able to join:

• People who have, or have had, another cancer — unless it was fully treated more than 5 years ago, or is a very early-stage cancer that can be completely cured with treatment.
• People who have cancer that has spread to the brain, or who have a history of brain metastases.
• People who have previously had an organ transplant.
• People who have had surgery on the head, chest, or abdomen within the past 6 months.
• People with severe liver disease (Child-Pugh class C) or significant fluid build-up in the abdomen (ascites).
• People with significant blood clots in the main portal vein or widespread tumour invasion of that vein.
• People whose blood clotting test results exceed acceptable levels, or who have had any bleeding or a tendency to bleed within the two months before enrolment.
• People who have an ongoing active infection within 7 days of finishing a course of antibiotic treatment.
• People with active heart artery disease, severe or unstable chest pain (angina), or a heart attack or new angina diagnosis within the past 12 months.
• People who have had a stroke, mini-stroke (TIA), blood clot in the lungs, or deep vein thrombosis within the past 12 months.
• People with moderate to severe heart failure (New York Heart Association class II or above).
• People with HIV infection or AIDS, active syphilis, or untreated active hepatitis B or C above specified levels.
• People with active autoimmune diseases requiring systemic treatment — though some stable autoimmune conditions managed without immune-suppressing medications (such as type 1 diabetes or hypothyroidism on hormone therapy) may still be considered (confirm with trial site).
• People with lung inflammation, non-infectious pneumonia, or uncontrolled conditions such as diabetes, high blood pressure, or pulmonary fibrosis.
• People who are pregnant, breastfeeding, or who test positive for pregnancy before the first dose.
• People with severe psychological or psychiatric conditions.
• People who have participated in another drug clinical trial within the past 4 weeks.
• People whom the trial investigator considers unsuitable based on any clinical, laboratory, or compliance concerns.

Important: Always verify eligibility with the trial site directly before applying.